Please login to the form below
HTA guidance from NICE, the SMC and the AWMSG
Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG).
Provided by Guidelines, it also features: NICE clinical guidelines, NICE quality standards, NICE evidence updates, NICE evidence summaries, independent professional body guidelines and (Scottish Intercollegiate Guidelines Network (SIGN) guidance.
No results were found
AstraZeneca's rare disease unit receives NICE recommendation for Wolman disease therapy in infants
27 Nov 2023
AstraZeneca's rare disease unit has received a recommendation from the National Institute for Health and Care Excellence (NICE) for the use of its enzyme replacement therapy in infants with Wolman ... Sean Richardson, vice president and general manager,
New report identifies key issues with NICE’s methods for evaluating Alzheimer’s drugs
22 Nov 2023
The development of disease-modifying dementia treatments (DMDTs) represents a "long-awaited change" in the management of the condition, NICE said. ... Both treatments target mild cognitive impairment and mild dementia due to Alzheimer’s disease and are
NICE recommends Chiesi’s alpha-mannosidosis enzyme replacement therapy
10 Nov 2023
The National Institute for Health and Care Excellence (NICE) has recommended Chiesi’s Lamzede (velmanase alfa) to treat the non-neurological signs and symptoms of mild-to-moderate alpha-mannosidosis, an ... Lamzede, which is designed to supplement or
NICE announces launch of refreshed support service for life sciences industry
8 Nov 2023
NICE Advice will support pharmaceutical and healthtech companies and provide patients with access to quality treatments and care. ... Jeanette Kusel, director of NICE Advice, said: “NICE Advice can help companies prepare for a technology appraisal, or
Novartis’ Cosentyx recommended by NICE for hidradenitis suppurativa
27 Oct 2023
Novartis’ Cosentyx (secukinumab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a treatment option for adults in England and Wales with active moderate-to-severe ... Additionally, the New Treatment Fund in Wales,
MGP’s Guidelines brand is trusted by over 58,000 healthcare professionals for concise clinical summaries of major primary and shared care guidelines in the UK. Through Guidelines, Guidelines for Nurses and Guidelines in Practice, MGP connect pharmaceutical and medical device companies to an engaged audience of GPs, GP commissioners and payers, nurses and allied healthcare professionals.
To discuss how we can support your guidance or implementation needs please contact marketing@mgp.co.uk
Subscribe to our email news alerts
- Roche to acquire Carmot Therapeutics in deal worth up to $3.1bn
- Eli Lilly’s Jaypirca granted FDA accelerated approval for non-Hodgkin lymphomas
- UK-India research project trialling easy-to-use UTI test to support fight against AMR
- Cancer Research UK and Guardant collaborate to advance cancer detection and treatment
- Give the gift of positive change
- Apple Vision Pro: challenges and opportunities for pharma
No results were found
PMHub
Twist Health
Not just another healthcare communications agency. We are a collection of award-winning industry experts focusing on bringing the very best...
